Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Georgiamune has raised $75.0M in total funding. The most recent round was Series A. The last funding was announced in August 2023.
Georgiamune's investors include General Catalyst, Catalio Capital Management, Verition Fund Management, Alexandria Venture Investments, Bioventures Investors.
Georgiamune is headquartered in Gaithersburg, United States.
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Georgiamune is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Georgiamune — Funding & Investors." VCBacked, August 9, 2023, https://www.vcbacked.co/company/georgiamune. Accessed August 1, 2026.
VCBacked. (2023). Georgiamune — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/georgiamune
{{cite web |title=Georgiamune — Funding & Investors |url=https://www.vcbacked.co/company/georgiamune |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated